2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Computer Vision, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

2290 Consensus genomic staging extends to smoldering myeloma, identifying patients at risk of progression and complements the 20/2/20 risk model

Mehmet Kemal Samur, PhD, Jill Corre Sr, PharmD2, Anil Aktas-Samur, PhD3, Srikanth Talluri, PhD4, Parth Shah, MD5, Joshua Rivera6, Yiyang Fan, B.S.7, Bahar Dakiki Korucu, MD8, Raphael E. Szalat, MD, PhD9, Mariateresa Fulciniti, PhD10, Kenneth Anderson, MD11, Adam S. Sperling, MD, PhD12, Giovanni Parmigiani, PhD13, Maria-Victoria Mateos Jr, MD, PhD14, Hervé Avet-Loiseau, MD, PhD,15, Nikhil Munshi, MD16
1 Dana Farber Cancer Institute, Boston, Massachusetts, United States
2 Institut Universitaire du Cancer de Toulouse - Oncopole, Université de Toulouse, Toulouse, France
3 Dana Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana Farber Cancer Institute, Boston, Massachusetts, United States
5 Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
6 Dana Farber Cancer Institute, Boston, Massachusetts, United States
7 University of Washington, Seattle, Washington, United States
8 Dana Farber Cancer Institute, Boston, Massachusetts, United States
9 Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts, United States
10 Dana Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana Farber Cancer Institute, Boston, Massachusetts, United States
12 Stanford University, Stanford, California, United States
13 Dana Farber Cancer Institute, Boston, Massachusetts, United States
14 University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain
15 Institut Universitaire du Cancer de Toulouse - Oncopole, Université de Toulouse, Toulouse, France
16 Dana Farber Cancer Institute, Boston, Massachusetts, United States

Introduction: Recent studies evaluating patients with smoldering multiple myeloma (SMM) progressing to MM, have shown no significant differences in somatic alterations and clonal structures between SMM and MM samples from the same patient. Moreover, we can hypothesize that presence of high-risk genomics identified in MM may also carry significant risk if present at SMM stage. To identify and develop a uniform genomic risk stratification at SMM stage, we have investigated the role of IMS-IMWG Consensus Genomic Staging (CGS) framework in SMM.

Methods: To test the validity of IMS CGS at early stages, we performed whole genome sequencing on 224 cases and collected additional samples from routine clinical evaluation with targeted sequencing that can report IMS CGS scoring. We analyzed the impact of CGS on SMM progression risk and whether it adds to 20-2-20 risk model.

Results: On our WGS dataset, we identified 16% of SMM patients with CGS high-risk signatures. Of these CGS high-risk SMM patients, 88% progressed to MM within 5 years of diagnosis, and 3 did not progress with more than 5 years of follow-up (OR=5.95, 95% CI= 1.70-20.98, p = 0.0018).  Median time to progression for CGS high risk was 1.22 years versus 3.61 years for low-risk cases (p < 0.0001). We further validated the utility of CGS in newly diagnosed SMM cases screened for routine clinical follow-up.

Combining CGS with 20/2/20, patients with presence of both CGS and 20/2/20 high-risk signature progressed within with a median progression time of 10 months, versus when both CGS and 20/2/20 were standard risk, the median was not reached (p < 0.0001). All patients with CGS high-risk progressed within 18 months. Interestingly, patients with CGS high-risk but 20/2/20 low or intermediate risk had similar progression time (median 11 months), while those with 20/2/20 high-risk and CGS standard risk had median TTP of 2.01 years. Importantly, combination of either 20/2/20 or CGS high-risk is  a strong predictor of early MM progression in SMM; median TTP was 18 months for high-risk patients, with 5-year PFS 15% (defined as CGS HR and/or 20/2/20 high risk), versus median not reached (5-year PFS 67%) for standard risk (CGS Standard risk AND 20/2/20 low or intermediate) (p < 0.0001).

Conclusion: CGS is a consensus predictor for newly diagnosed MM. Our data here shows that it is also a predictor for progression in SMM. These results are also biologically meaningful, as it suggests that what is high-risk in MM has similar biological impact at SMM stage. Multiple recent studies have identified various genomic correlates of high-risk SMM, some of them are complementary or overlapping. However, based on our results, estimation of genomic changes by sequencing-based clinical tests now routinely incorporated in MM evaluation, may provide optimal and convenient risk stratification in SMM. In conclusion, when patients are CGS positive they should be considered as high-risk SMM and in combination with 20/2/20 we can now capture rapid progressors that may require therapeutic consideration.

Mehmet Kemal Samur, PhD: BMS - Research Funding; K36 Therapeutics, CodingBio, Abbvie, Neuberg Center for Genomic Medicine - Consultancy (Includes expert testimony)